Do cells need CDK2 and ... Bcr-Abl?

Cell Death and Differentiation

Volumn 11, Issue 3, 2004, Pages 249-251

  Blagosklonny, M V ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CAMPTOTHECIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; HEAT SHOCK PROTEIN 70; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BCL XL; STAT5 PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN HL 60; DOWN REGULATION; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CDC2-CDC28 KINASES; CYCLIN-DEPENDENT KINASE 2; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MODELS, BIOLOGICAL; PIPERAZINES; PYRIMIDINES;

EID: 1542299692     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401361     Document Type: Article

References (48)

1. Tetsu O and McCormick F (2003) Cancer Cell 3: 233-245
2. Pardee AB (1974) Proc. Natl. Acad. Sci. USA 71: 1286-1290
3. Sherr CJ and McCormick F (2002) Cancer Cell 2: 103-112
4. Blagosklonny MV and Pardee AB (2002) Cell Cycle 1: 103-110
5. DeGregori J et al. (1995) Genes Dev. 9: 2873-2887
6. Santoni-Rugiu E et al. (2000) Mol. Cell. Biol. 20: 3497-3509
7. Darzynkiewicz Z (2000) J. Natl. Cancer Inst. 92: 1184-1185
8. Pardee AB (2002) Cancer Biol. Ther. 1: 426-427
9. Ortega S et al. (2003) Nat. Genet. 35: 25-31
10. Aleem E et al. (2004) Cell Cycle 3: 35-37
11. Berthet C et al. (2003) Curr. Biol. 13: 1775-1785
12. Mendez J (2003) Cell 114: 398-399
13. Roberts JM and Scherr CJ (2003) Nat. Genet. 35: 9-10
14. Gladden AB and Diehl JA (2003) Cancer Cell 4: 160-162
15. Traganos F (2004) Cell Cycle 3: 32-34
16. Geng Y et al. (2003) Cell 114: 431-443
17. Fischer PM and Lane DP (2000) Curr. Med. Chem. 7: 1213-1245
18. Dancey J and Sausville EA (2003) Nat. Rev. Drug Discovery 2: 296-313
19. Druker BJ et al. (2001) N. Engl. J. Med. 344: 1031-1037
20. Druker BJ (2002) Oncogene 21: 8541-8546
21. Sawyers CL (2002) Cancer Cell 1: 13-15
22. Dan S, Naito M and Tsuruo T (1998) Cell Death Differ. 5: 710-715
23. Fang G et al. (2000) Blood 96: 2246-2253
24. McGahon A et al. (1994) Blood 83: 1179-1187
25. Amarante-Mendes GP et al. (1998) Cell Death Differ. 5: 298-306
26. Amarante-Mendes GP et al. (1998) Blood 91: 1700-1705
27. Cortez D, Reuther G and Pendergast AM (1997) Oncogene 15: 2333-2342
28. Nimmanapalli R et al. (2002) Cancer Res. 62: 5761-5769
29. Garrido C et al. (2003) Cell Cycle 2: 579-584
30. Reuther JY et al. (1998) Genes Dev. 12: 968-981
31. Plattner R and Pendergast AM (2003) Cell Cycle 2: 273-274
32. Hoover RR et al. (2001) Oncogene 20: 5826-5835
33. Neshat MS et al. (2000) Mol. Cell. Biol. 20: 1179-1186
34. Sattlermc M and Griffin JD (2003) Semin. Hematol. 40: S4-S10
35. Afar DE et al. (1995) Proc. Natl. Acad. Sci. USA 92: 9540-9544
36. Jena N et al. (2002) Cancer Res. 62: 535-541
37. Deininger MW et al. (2001) Cancer Res. 61: 8005-8013
38. Jiang Y et al. (2000) Proc. Natl. Acad. Sci. USA 19: 10538-10543
39. Blagosklonny MV et al. (2001) Leukemia 15: 1537-1543
40. McGahon A et al. (1994) Blood 83: 1179-1187
41. Skorski T (2002) Oncogene 21: 8591-8604
42. Horita M et al. (2000) J. Exp. Med. 191: 977-984
43. Amarante-Mendes GP et al. (1998) Oncogene 16: 1383-1390
44. Blagosklonny MV (2003) EMBO Rep. 4: 358-362
45. Chen YN et al. (1999) Proc. Natl. Acad. Sci. USA 96: 4325-4329
46. Parisi T et al. (2003) EMBO J. 22: 4794-4803
47. Blagosklonny MV and Darzynkiewicz Z (2002) Cell Cycle 1: 375-382
48. Chen X et al. (2000) J. Natl. Cancer Inst. 92: 1999-2008